ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies

NCT01110473 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Lymphoblastic Leukemia
Acute Myelogenous Leukemia
B-cell Chronic Lymphocytic Leukemia
Chronic Myelogenous Leukemia
Myelodysplasia

Interventions

DRUG: ABT-348
DRUG: ABT-348
DRUG: ABT-348 and azacitidine
DRUG: ABT-348

Sponsor

AbbVie (prior sponsor, Abbott)